Enliven Therapeutics (ELVN) Non Operating Income (2019 - 2025)
Enliven Therapeutics' (ELVN) quarterly Non Operating Income came in at -$2000.0 in Q2 2025, down 100.04% year-on-year from $4.7 million in Q2 2024, and up 95.74% quarter-over-quarter from -$47000.0 in Q1 2025.
Enliven Therapeutics (ELVN) Non Operating Income (2019 - 2025) Analysis & Trends
Enliven Therapeutics has disclosed Non Operating Income across 7 years of filings, most recently posting -$2000.0 for Q2 2025.
- Non Operating Income for Q2 2025 came in at -$2000.0, down 100.04% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2000.0 (up 99.94% YoY), and the FY2025 annual result was -$49000.0, changed N/A from the prior year.
- Non Operating Income came in at -$2000.0 for Q2 2025 at Enliven Therapeutics, up from -$47000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $4.7 million in Q2 2024 to a low of -$11.8 million in Q4 2024.
- The 5-year median for Non Operating Income is $151500.0 (2021), against an average of $64666.7.
- Peak annual rise in Non Operating Income reached 18722.22% in 2023, while the deepest fall reached 1504.24% in 2023.
- Enliven Therapeutics' Non Operating Income stood at $176000.0 in 2021, then soared by 248.3% to $613000.0 in 2022, then plunged by 1504.24% to -$8.6 million in 2023, then slumped by 37.24% to -$11.8 million in 2024, then jumped by 99.98% to -$2000.0 in 2025.
- The last three Non Operating Income figures came in at -$2000.0 (Q2 2025), -$47000.0 (Q1 2025), and -$11.8 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 444,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 9.35 Mn |
| 10 | Enliven Therapeutics | 2.32 Bn | 2.32 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -2,000.00 |
| Mar 31, 2025 | -47,000.00 |
| Dec 31, 2024 | -11.81 Mn |
| Sep 30, 2024 | 3.91 Mn |
| Jun 30, 2024 | 4.65 Mn |
| Mar 31, 2024 | 3.25 Mn |
| Dec 31, 2023 | -8.61 Mn |
| Sep 30, 2023 | 3.48 Mn |
| Jun 30, 2023 | 3.41 Mn |
| Mar 31, 2023 | 1.69 Mn |
| Dec 31, 2022 | 613,000.00 |
| Sep 30, 2022 | 380,000.00 |
| Jun 30, 2022 | 127,000.00 |
| Mar 31, 2022 | 9,000.00 |
| Dec 31, 2021 | 176,000.00 |
| Sep 30, 2021 | -18,000.00 |
| Jun 30, 2021 | 8,000.00 |
| Mar 31, 2021 | -60,000.00 |
| Dec 31, 2020 | -83,000.00 |
| Sep 30, 2020 | -55,000.00 |